
Matinas BioPharma Holdings, Inc.
97
Recent developments include the announcement of a merger with GH Power and sale of MAT2203 and the LNC platform to Azurity Pharmaceuticals, multiple NYSE American non-compliance notices with an accepted compliance plan, and ongoing challenges following the halt of MAT2203 development.
- Matinas BioPharma announced a merger with GH Power and sold its LNC platform and MAT2203 to Azurity Pharmaceuticals in July 2026 [N3].
- The company received additional NYSE American non-compliance notices related to stockholders' equity and governance, with a compliance plan accepted by the exchange in June 2026 [N4].
- Matinas BioPharma received a further NYSE American non-compliance notice in September 2026 [N1].
- The company faces an uncertain future after halting development of MAT2203 and implementing significant workforce reductions [N5].
Matinas BioPharma Holdings, Inc. is focused on developing therapies using its proprietary lipid nanocrystal (LNC) platform technology. Its lead candidate, MAT2203, is an oral formulation of amphotericin B designed to treat invasive fungal infections with improved safety and oral administration compared to existing IV formulations. MAT2203 completed a Phase 2 trial showing positive efficacy and safety results and was positioned for a Phase 3 registration trial (ORALTO) targeting invasive aspergillosis. The company paused clinical development and reduced workforce in late 2024, seeking partnerships or sale of MAT2203. In 2026, Matinas announced a merger with GH Power and sold MAT2203 and the LNC platform to Azurity Pharmaceuticals. The company continues to maintain regulatory and intellectual property obligations and supports compassionate use programs. It faces challenges including NYSE American non-compliance notices and risks related to its business combination and stock sale agreements.
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company developing MAT2203, an oral antifungal drug using its lipid nanocrystal platform. The company has paused clinical development of MAT2203 and reduced workforce while seeking partnerships or sale of the asset. It has entered a merger agreement with GH Power and sold MAT2203 and the LNC platform to Azurity Pharmaceuticals. The company faces NYSE American non-compliance notices related to stockholders' equity and governance, with a compliance plan accepted. Financially, as of September 30, 2026, it reported $1.936 million in cash, a net loss of $1.765 million for the quarter, and liquidity ratios indicating moderate short-term liquidity. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
The company’s LNC platform and MAT2203 have demonstrated clinical efficacy and safety in Phase 2 trials, with regulatory agreement on a Phase 3 trial design. The oral formulation of amphotericin B could provide a safer, more convenient treatment for invasive fungal infections, addressing a significant unmet need. The sale of MAT2203 and the LNC platform to Azurity Pharmaceuticals and the merger with GH Power may provide strategic resources and partnerships to advance development and commercialization. Continued maintenance of intellectual property and regulatory engagement supports potential future value creation.
Matinas BioPharma has paused clinical development of its lead product MAT2203 and reduced workforce significantly, reflecting operational and financial challenges. The company faces multiple NYSE American non-compliance notices related to stockholders' equity and governance, risking delisting and impacting liquidity and capital raising ability. The success of the business combination and stock sale agreements is uncertain and subject to multiple conditions. The company’s financial position shows net losses and limited cash resources, with risks that it may need to pursue winddown or liquidation if additional funding or partnerships are not secured.
Matinas BioPharma's moat centers on its proprietary lipid nanocrystal (LNC) platform technology enabling oral delivery of amphotericin B, a potent antifungal drug traditionally limited to IV administration due to toxicity. The LNC platform's ability to improve safety and enable oral dosing addresses significant unmet medical needs in invasive fungal infections. The company has developed intellectual property around MAT2203 and the LNC platform, supported by clinical trial data and regulatory designations such as Qualified Infectious Disease Product and Orphan Drug status. However, the moat is challenged by halted internal development, reliance on partnerships, and financial and regulatory compliance risks.
• Regulatory and Listing Compliance Risks: The company has received multiple NYSE American non-compliance notices related to stockholders' equity and governance, with a compliance plan accepted but ongoing risk of delisting which could materially impact liquidity, trading, and capital raising ability [N1][N4][S2].
• Operational and Development Risks: Clinical development of MAT2203 has been paused, and workforce reduced by 80%, reflecting operational challenges. The company depends on consummating partnerships or sale of MAT2203 to advance development [S1][N5].
• Financial Risks: The company reported net losses and limited cash and liquidity as of September 30, 2026. Failure to secure additional funding or complete business combination transactions could lead to winddown or liquidation [S2].
• Business Combination and Transaction Risks: The merger with GH Power and sale of MAT2203 and the LNC platform to Azurity Pharmaceuticals are subject to conditions and risks including stockholder approvals, regulatory approvals, and potential delays or failures that could adversely affect operations and financial condition [N3][S2].
Business trends: Paused clinical development of MAT2203, focus on partnerships and strategic transactions including merger and asset sale.
Execution milestones: Completion of business combination with GH Power, sale of MAT2203 and LNC platform to Azurity Pharmaceuticals, and regulatory compliance plan implementation.
Key risks: NYSE American listing compliance and potential delisting, financial constraints, operational challenges from halted development, and uncertainties in transaction completions.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on therapies using its lipid nanocrystal (LNC) platform technology [S1].
- The lead product candidate is MAT2203, an oral formulation of amphotericin B designed to treat invasive fungal infections with improved safety and oral administration compared to IV amphotericin B [S1].
- MAT2203 completed a Phase 2 trial (EnACT) for cryptococcal meningitis showing positive safety and efficacy signals, including fungal clearance and survival rates [S1].
- A Phase 3 registration trial (ORALTO) for MAT2203 targeting invasive aspergillosis patients with limited treatment options was designed in agreement with the FDA [S1].
- The company paused further clinical development of MAT2203 and reduced workforce by 80% in late 2024, seeking partnerships or sale of MAT2203 to advance development [S1].
- Matinas BioPharma continues to maintain the MAT2203 IND, intellectual property, and compassionate use programs despite the development pause [S1].
- The company announced a merger agreement with GH Power and sold the LNC platform and MAT2203 to Azurity Pharmaceuticals in July 2026 [N3].
- Matinas BioPharma has received multiple NYSE American non-compliance notices related to stockholders' equity and governance issues, with a compliance plan accepted by the exchange [N1][N4][S2].
- Financial snapshot as of September 30, 2026: cash and equivalents $1.936 million, current assets $2.119 million, current liabilities $1.193 million, net loss $1.765 million for the quarter, basic and diluted EPS of -$9.35 [S2].
- Liquidity ratios as of September 30, 2026: current ratio 1.78, cash ratio 2.04, indicating moderate short-term liquidity [S2].
- The company has faced challenges including halted MAT2203 development, workforce reductions, and uncertainty about future operations [N5][S1].
- Matinas BioPharma has engaged in financing rounds, including a $3.3 million preferred stock and warrants financing in early 2025 [N8].
- Board appointments include Keith Murphy, Edward Neugeboren, Dr. Robin L. Smith, and Evelyn D’An in 2025 [N7][N8].
- The company’s common stock is listed on the NYSE American but is at risk of delisting due to non-compliance with listing standards related to stockholders' equity and other requirements [S2].
- The company’s business combination and stock sale agreements with GH Power include conditions and risks that could affect completion and ongoing operations [S2].
Generated 2026-11-17
- S1 | 2026-03-31 | 10-K
- S2 | 2026-11-16 | 10-Q
- N1 | 2026-09-07 | www.nasdaq.com | Matinas BioPharma Receives NYSE American Non-Compliance Notice | https://www.nasdaq.com/articles/matinas-biopharma-receives-nyse-american-non-compliance-notice
- N2 | 2026-07-18 | www.nasdaq.com | Weekly Buzz: NVS, MRK Win FDA Nod; LLY Snaps Up ATAI; MANE Shines On Hair Loss Data | https://www.nasdaq.com/articles/weekly-buzz-nvs-mrk-win-fda-nod-lly-snaps-atai-mane-shines-hair-loss-data
- N3 | 2026-07-14 | www.nasdaq.com | Matinas BioPharma To Merge With GH Power; Sells LNC Platform And MAT2203 To Azurity Pharmaceuticals | https://www.nasdaq.com/articles/matinas-biopharma-merge-gh-power-sells-lnc-platform-and-mat2203-azurity-pharmaceuticals
- N4 | 2026-06-29 | www.nasdaq.com | Matinas BioPharma Receives Additional NYSE Notice Of Non-Compliance; Compliance Plan Accepted | https://www.nasdaq.com/articles/matinas-biopharma-receives-additional-nyse-notice-non-compliance-compliance-plan-accepted
- N5 | 2026-05-10 | www.nasdaq.com | Matinas BioPharma Faces Uncertain Future After Halting MAT2203 Development | https://www.nasdaq.com/articles/matinas-biopharma-faces-uncertain-future-after-halting-mat2203-development
- N6 | 2025-03-23 | www.nasdaq.com | $MTNB Earnings Preview: Recent $MTNB Insider Trading, Hedge Fund Activity, and More | https://www.nasdaq.com/articles/mtnb-earnings-preview-recent-mtnb-insider-trading-hedge-fund-activity-and-more
- N7 | 2025-03-11 | www.nasdaq.com | Matinas BioPharma Appoints Keith Murphy and Edward Neugeboren to Board of Directors | https://www.nasdaq.com/articles/matinas-biopharma-appoints-keith-murphy-and-edward-neugeboren-board-directors
- N8 | 2025-02-13 | www.nasdaq.com | Matinas BioPharma Holdings, Inc. Secures $3.3 Million in Financing and Appoints Dr. Robin L. Smith to Board of Directors | https://www.nasdaq.com/articles/matinas-biopharma-holdings-inc-secures-33-million-financing-and-appoints-dr-robin-l-smith
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


